Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Core Viewpoint - Mereo BioPharma Group plc is actively engaged in the development of innovative therapeutics for rare diseases and will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 12, 2025 [1][2]. Company Overview - Mereo BioPharma focuses on rare diseases with two main product candidates: setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) [3]. - The partnership with Ultragenyx Pharmaceutical includes potential milestone payments of up to $245 million and royalties on commercial sales in Ultragenyx territories, while Mereo retains EU and UK commercial rights [3]. - Setrusumab has received multiple designations from regulatory bodies, including orphan designation from the EMA and FDA, and Breakthrough Therapy designation from the FDA [3]. - Alvelestat has also received U.S. Orphan Drug Designation and Fast Track designation from the FDA, along with Orphan Designation from the European Commission [3]. - Mereo has oncology product candidates, including etigilimab and navicixizumab, with navicixizumab partnered with Feng Biosciences in a global licensing agreement [3]. Upcoming Events - Dr. Denise Scots-Knight, CEO of Mereo, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 12, 2025, at 8:40 am ET [1]. - A live audio webcast of the event will be available on the company's website, with an archived replay accessible for two weeks post-event [2].